Metraipolis › archive › dc_97aee85c2c3a

TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response — Europe PMC PMID:42210306

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42210306
DOI
10.1186/s41065-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-10-17T06:40:43.446Z
SHA-256 of the archived text
3fd6e0bbd01090659c2587640f7645f40a2e47e65bad4035ac57d25c122cb7ef
Stable URL of this page
https://metraipolis.com/documento/dc_97aee85c2c3a

How to cite

TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response — Europe PMC PMID:42210306 — Europe PMC (en), https://europepmc.org/article/MED/42210306 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_97aee85c2c3a (Metraipolis archive dc_97aee85c2c3a, sha256 3fd6e0bbd01090659c2587640f7645f40a2e47e65bad4035ac57d25c122cb7ef)
BibTeX
@misc{dc97aee85c2c3a,
  title = {TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response — Europe PMC PMID:42210306},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42210306},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_97aee85c2c3a; sha256 3fd6e0bbd01090659c2587640f7645f40a2e47e65bad4035ac57d25c122cb7ef},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42210306. Agents can read the archived copy with the MCP tool read_document.